MedTrace Logo

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

NCT00176202 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-11-05

Study results available
· View outcomes & findings →

Summary

The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.

Conditions

Interventions

DRUG

Divalproex Sodium

Divalproex sodium is a mood stabilizer

DRUG

risperidone

Risperidone is a second generation antipsychotic and antimanic drug

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Mani Pavuluri, MD · University of Ilinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176202 on ClinicalTrials.gov